-
Heathrow still Europe's busiest airport, but Istanbul gaining fast
-
Highest storm alert lifted in Spain, one woman missing
-
Shell profits climb despite falling oil prices
-
Pakistan will seek govt nod in potential India T20 finals clash
-
China shuns calls to enter nuclear talks after US-Russia treaty lapses
-
German factory orders rise at fastest rate in 2 years in December
-
Nigeria president deploys army after new massacre
-
Ukraine, Russia, US start second day of war talks
-
Nepal's youth lead the charge in the upcoming election
-
Sony hikes forecasts even as PlayStation falters
-
Rijksmuseum puts the spotlight on Roman poet's epic
-
Trump fuels EU push to cut cord with US tech
-
Fearless talent: Five young players to watch at the T20 World Cup
-
India favourites as T20 World Cup to begin after chaotic build-up
-
Voter swings raise midterm alarm bells for Trump's Republicans
-
Australia dodges call for arrest of visiting Israel president
-
Countries using internet blackouts to boost censorship: Proton
-
Top US news anchor pleads with kidnappers for mom's life
-
Thailand's pilot PM on course to keep top job
-
The coming end of ISS, symbol of an era of global cooperation
-
New crew set to launch for ISS after medical evacuation
-
Family affair: Thailand waning dynasty still election kingmaker
-
Japan's first woman PM tipped for thumping election win
-
Stocks in retreat as traders reconsider tech investment
-
LA officials call for Olympic chief to resign over Epstein file emails
-
Ukraine, Russia, US to start second day of war talks
-
Fiji football legend returns home to captain first pro club
-
Trump attacks US electoral system with call to 'nationalize' voting
-
Barry Manilow cancels Las Vegas shows but 'doing great' post-surgery
-
US households become increasingly strained in diverging economy
-
Four dead men: the cold case that engulfed a Colombian cycling star
-
Super Bowl stars stake claims for Olympic flag football
-
On a roll, Brazilian cinema seizes its moment
-
Rising euro, falling inflation in focus at ECB meeting
-
AI to track icebergs adrift at sea in boon for science
-
Indigenous Brazilians protest Amazon river dredging for grain exports
-
Google's annual revenue tops $400 bn for first time, AI investments rise
-
Last US-Russia nuclear treaty ends in 'grave moment' for world
-
Man City brush aside Newcastle to reach League Cup final
-
Guardiola wants permission for Guehi to play in League Cup final
-
Boxer Khelif reveals 'hormone treatments' before Paris Olympics
-
'Bad Boy,' 'Little Pablo' and Mordisco: the men on a US-Colombia hitlist
-
BHP damages trial over Brazil mine disaster to open in 2027
-
Dallas deals Davis to Wizards in blockbuster NBA trade: report
-
Iran-US talks back on, as Trump warns supreme leader
-
Lens cruise into French Cup quarters, Endrick sends Lyon through
-
No.1 Scheffler excited for Koepka return from LIV Golf
-
Curling quietly kicks off sports programme at 2026 Winter Olympics
-
Undav pokes Stuttgart past Kiel into German Cup semis
-
Germany goalkeeper Ter Stegen to undergo surgery
US govt sends drugmakers initial offers in price talks
The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.
The move comes as President Joe Biden pushes to rein in health care costs ahead of November's election.
The negotiation program came on the back of Biden's landmark Inflation Reduction Act, a major package of energy transition policy and social reforms.
This allowed Medicare, the federal health insurance for seniors, to start negotiating drug costs -- a first in its nearly 60-year existence.
"This is the first time ever that Medicare is not accepting the drug prices the pharmaceutical companies set," the White House said in a statement on Thursday.
It did not reveal how much it offered for each drug.
A Johnson & Johnson spokesperson told AFP the company has received an initial price from the government but said it was "respecting the confidential nature of the process."
Last October, major drugmakers behind 10 selected medicines for serious illnesses grudgingly agreed to negotiate on cutting prices.
But pharmaceutical companies have pushed back against the initiative, earlier saying that they came on board as they had no choice.
While the US government is initially limited to picking 10 drugs for price talks, it can expand the program in subsequent years.
The drugs include Farxiga by AstraZeneca used against diabetes, Entresto by Novartis to treat heart failure, as well as anticoagulant Eliquis -- used by millions of Medicare beneficiaries.
According to the White House, nine million seniors on Medicare were prescribed the 10 drugs in 2022, spending some $3.4 billion out-of-pocket that year.
The statement also took aim at Big Pharma, which the White House said "charged Americans two to three times more" than in other countries, even when accounting for rebates and discounts.
Biden, who is campaigning for reelection with a large focus on easing voters' financial burdens, said in a separate statement: "My Administration won't stop fighting to lower health care costs for seniors and families."
New negotiated prices for the 10 prescription drugs are set to be announced later this year.
Medicare is expected to negotiate prices for up to 60 drugs over the next four years, and up to an additional 20 drugs each year after that.
Several companies have taken legal action challenging the provisions.
A.AbuSaada--SF-PST